相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
Tatsunori Shimoi et al.
BREAST CANCER (2020)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
Saverio Cinieri et al.
CLINICAL BREAST CANCER (2017)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz et al.
BMC CANCER (2016)
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial
A. Welt et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
Tsutomu Takashima et al.
LANCET ONCOLOGY (2016)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Christoph Zielinski et al.
LANCET ONCOLOGY (2016)
Capecitabine Combined With Docetaxel Versus Vinorelbine Followed by Capecitabine Maintenance Medication for First-Line Treatment of Patients With Advanced Breast Cancer: Phase 3 Randomized Trial
Jiayu Wang et al.
CANCER (2015)
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial
D. Yamamoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
Istvan Lang et al.
LANCET ONCOLOGY (2013)
Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects
Everardo D. Saad et al.
ACTA ONCOLOGICA (2012)
Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer
Martin R. Stockler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Estimating an EQ-5D population value set: the case of Japan
A Tsuchiya et al.
HEALTH ECONOMICS (2002)
Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
DC Talbot et al.
BRITISH JOURNAL OF CANCER (2002)
The use of oral cytotoxic and cytostatic drugs in cancer treatment
A Sparreboom et al.
EUROPEAN JOURNAL OF CANCER (2002)
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
JA O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2001)
分享论文
